Magnetically stimulated ciprofloxacin release from polymeric microspheres entrapping iron oxide nanoparticles

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 4447-4458

  Sirivisoot, Sirinrath ^a   Harrison, Benjamin S ^b  

^a KING MONGKUT'S UNIVERSITY OF TECHNOLOGY THONBURI   (Thailand)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Antibacterial; Hematite; Maghemite; Staphylococcus aureus

Indexed keywords

CIPROFLOXACIN; FERRIC OXIDE; IRON OXIDE NANOPARTICLE; MAGNETIC NANOPARTICLE; MICROSPHERE; NANOPARTICLE; POLYCAPROLACTONE; POLYMER; UNCLASSIFIED DRUG; MAGNETITE NANOPARTICLE; POLYESTER;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG TARGETING; FIBROBLAST; FIBROBLAST CULTURE; IN VITRO STUDY; MACROPHAGE; MAGNETIC FIELD; MAGNETIC STIMULATION; MOUSE; NANOENCAPSULATION; NANOFABRICATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; 3T3 CELL LINE; ANIMAL; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS;

BACTERIA (MICROORGANISMS); STAPHYLOCOCCUS AUREUS;

ANIMALS; CELL SURVIVAL; CIPROFLOXACIN; MAGNETITE NANOPARTICLES; MICE; MICROSPHERES; NIH 3T3 CELLS; POLYESTERS;

EID: 84937579473     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S82830     Document Type: Article

References (47)

1. Pankhurst QA, Connolly J, Jones SK, Dobson J. Applications of magnetic nanoparticles in biomedicine. J Phys D Appl Phys. 2003;36:R167–R181.
2. Berry CC, Curtis ASG. Functionalisation of magnetic nanoparticles for applications in biomedicine. J Phys D Appl Phys. 2003;36:R198–R206.
3. Moroz P, Jones SK, Gray BN. Magnetically mediated hyperthermia: current status and future directions. Int J Hyperthermia. 2002;18(4):267–284.
4. Mahmoudi M, Simchi A, Milani AS, Stroeve P. Cell toxicity of superparamagnetic iron oxide nanoparticles. J Colloid Interface Sci. 2009;336(2):510–518.
5. Coey JMD. Magnetism and Magnetic Materials. Cambridge: Cambridge University Press; 2010.
6. Hoare T, Santamaria J, Goya GF, et al. A magnetically triggered composite membrane for on-demand drug delivery. Nano Lett. 2009;9(10):3651–3657.
7. Tai LA, Tsai PJ, Wang YC, Wang YJ, Lo LW, Yang CS. Thermosensitive liposomes entrapping iron oxide nanoparticles for controllable drug release. Nanotechnology. 2009;20(13):135101.
8. Muller-Schulte D, Schmitz-Rode T. Thermosensitive magnetic polymer particles as contactless controllable drug carriers. J Magn Magn Mater. 2006;302(1):267–271.
9. Zhang J, Misra RD. Magnetic drug-targeting carrier encapsulated with thermosensitive smart polymer: core-shell nanoparticle carrier and drug release response. Acta Biomater. 2007;3(6):838–850.
10. Hu S-H, Tsai C-H, Liao C-F, Liu D-M, Chen S-Y. Controlled rupture of magnetic polyelectrolyte microcapsules for drug delivery. Langmuir. 2008;24(20):11811–11818.
11. Hu S-H, Chen S-Y, Liu D-M, Hsiao C-S. Core/single-crystal-shell nanospheres for controlled drug release via a magnetically triggered rupturing mechanism. Adv Mater. 2008;20(14):2690–2695.
12. Hu S-H, Liu T-Y, Huang H-Y, Liu D-M, Chen S-Y. Magnetic-sensitive silica nanospheres for controlled drug release. Langmuir. 2007;24(1):239–244.
13. Dilnawaz F, Singh A, Mohanty C, Sahoo SK. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials. 2010;31(13):3694–3706.
14. Li R, Wu R, Zhao L, et al. Folate and iron difunctionalized multiwall carbon nanotubes as dual-targeted drug nanocarrier to cancer cells. Carbon N Y. 2011;49(5):1797–1805.
15. Subbiahdoss G, Sharifi S, Grijpma DW, et al. Magnetic targeting of surface-modified superparamagnetic iron oxide nanoparticles yields antibacterial efficacy against biofilms of gentamicin-resistant staphylococci. Acta Biomater. 2012;8(6):2047–2055.
16. Sirivisoot S, Pareta RA, Webster TJ. A conductive nanostructured polymer electrodeposited on titanium as a controllable, local drug delivery platform. J Biomed Mater Res A. 2011;99(4):586–597.
17. Sirivisoot S, Pareta R, Webster TJ. Electrically controlled drug release from nanostructured polypyrrole coated on titanium. Nanotechnology. 2011;22(8):085101.
18. Sirivisoot S, Harrison BS. Skeletal myotube formation enhanced by electrospun polyurethane carbon nanotube scaffolds. Int J Nanomedicine. 2011;6:2483–2497.
19. Xu H, Cheng L, Wang C, Ma X, Li Y, Liu Z. Polymer encapsulated upconversion nanoparticle/iron oxide nanocomposites for multimodal imaging and magnetic targeted drug delivery. Biomaterials. 2011;32(35):9364–9373.
20. Wang S, Guo S, Cheng L. Disodium norcantharidate loaded poly([var epsilon]-caprolactone) microspheres: I. Preparation and evaluation. Int J Pharm. 2008;350(1–2):130–137.
21. Pitt CG. Poly(ε-caprolactone) and its copolymers. In: Chasin M, Langer R, editors. Biodegradable Polymer as Drug Delivery Systems. New York, NY: Marcel Decker Inc; 1990:71–120.
22. Kim SY, Lee YM. Taxol-loaded block copolymer nanospheres composed of methoxy poly(ethylene glycol) and poly(ε-caprolactone) as novel anticancer drug carriers. Biomaterials. 2001;22(13):1697–1704.
23. Lamprecht A, Torres HR, Schäfer U, Lehr C-M. Biodegradable microparticles as a two-drug controlled release formulation: a potential treatment of inflammatory bowel disease. J Control Release. 2000;69(3):445–454.
24. Lamprecht A, Ubrich N, Hombreiro Pérez M, Lehr C, Hoffman M, Maincent P. Influences of process parameters on nanoparticle preparation performed by a double emulsion pressure homogenization technique. Int J Pharm. 2000;196(2):177–182.
25. Gristina AG. Biomaterial-centered infection: microbial adhesion versus tissue integration. Science. 1987;237(4822):1588–1595.
26. Khalil H, Williams RJ, Stenbeck G, Henderson B, Meghji S, Nair SP. Invasion of bone cells by Staphylococcus epidermidis. Microbes Infect. 2007;9(4):460–465.
27. Stratton C. Fluoroquinolone antibiotics: properties of the class and individual agents. Clin Ther. 1992;14(3):348–375.
28. Jeong YI, Na HS, Seo DH, et al. Ciprofloxacin-encapsulated poly(dl-lactide-co-glycolide) nanoparticles and its antibacterial activity. Int J Pharm. 2008;352(1–2):317–323.
29. Armstrong EP, Friedman AD. Bone and joint infections. In: DiPiro JT, Talbert RL, Yee GC, et al, editors. Pharmacotherapy: A Pathophysiologic Approach. 8th ed. New York, NY: McGraw-Hill; 2011:2029–2039.
30. Lew DP, Waldvogel FA. Use of quinolones in osteomyelitis and infected orthopaedic prosthesis. Drugs. 1999;58(Suppl 2):85–91.
31. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2006. CLSI document M100-S16 [ISBN 1-56238-625-5].
32. Wiegand I, Hilpert K, Hancock RE. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc. 2008;3(2):163–175.
33. Pascual-Reguera MI, Parras GP, Diamp AM. Solid-phase UV spectrophotometric method for determination of ciprofloxacin. Microchem J. 2004;77(1):79–84.
34. Kang YS, Risbud S, Rabolt JF, Stroeve P. Synthesis and characterization of nanometer-size Fe3O4 and γ-Fe2O3 particles. Chem Mater. 1996;8:2209–2211.
35. Bee A, Massart R, Neveu S. Synthesis of very fine maghemite particles. J Magn Magn Mater. 1995;149:6–9.
36. Lode H. Evidence of different profiles of side effects and drug-drug interactions among the quinolones – the pharmacokinetic standpoint. Chemotherapy. 2001;47(Suppl 3):24–31. [discussion 44–48].
37. Masadeh MM, Karasneh GA, Al-Akhras MA, et al. Cerium oxide and iron oxide nanoparticles abolish the antibacterial activity of ciprofloxacin against gram positive and gram negative biofilm bacteria. Cytotechnology. 2015;67(3):427–435.
38. He S, Feng Y, Gu N, Zhang Y, Lin X. The effect of γ-Fe2O3 nanoparticles on Escherichia coli genome. Environ Pollut. 2011;159(2):3468–3473.
39. Azam A, Ahmed AS, Oves M, Khan MS, Habib SS, Memic A. Antimicrobial activity of metal oxide nanoparticles against Gram-positive and Gram-negative bacteria: a comparative study. Int J Nanomedicine. 2012;7:6003–6009.
40. Rakshit S, Sarkar D, Elzinga EJ, Punamiya P, Datta R. Mechanisms of ciprofloxacin removal by nano-sized magnetite. J Hazard Mater. 2013;24(6–247):221–226.
41. Tang Y, Guo H, Xiao L, Yu S, Gao N, Wang Y. Synthesis of reduced graphene oxide/magnetite composites and investigation of their adsorption performance of fluoroquinolone antibiotics. Colloids Surf A Physicochem Eng Asp. 2013;424:74–80.
42. Woodruff MA, Hutmacher DW. The return of a forgotten polymer – polycaprolactone in the 21st century. Prog Polym Sci. 2010;35:1217–1256.
43. Sinha VR, Bansal K, Kaushik R, Kumria R, Trehan A. Poly-ε-caprolactone microspheres and nanospheres: an overview. Int J Pharm. 2004;1(18):1–23.
44. Bosworth LA, Downes S. Physicochemical characterization of degrading polycaprolactone scaffolds. Polym Degrad Stab. 2010;95:2269–2276.
45. Sobczak M. Synthesis and characterization of polyester conjugates of ciprofloxacin. Eur J Med Chem. 2010;45:3844–3849.
46. Puga AM, Rey-rico A, Magarinos B, Alvarez-Lorenzo C, Concheiro A. Hot melt poly-e-caprolactone/poloxamine implantable matrices for sustained delivery of ciprofloxacin. Acta Biomater. 2012;8(4):1507–1518.
47. Lam CXF, Teoh SH, Hutmacher DW. Comparison of the degradation of polycaprolactone and polycaprolactone–(beta-tricalcium phosphate) scaffolds in alkaline medium. Polym Int. 2007;56:718–728.